If the number of responders (for example, 30% pain reduction) was not reported, a validated imputation method to calculate pain reduction rates from reported means and standard deviations was used [ 20, 23].
In addition, the effect of treatment upon two calculated total pain scores combining the individual BB entries and pain killer intake was calculated.
The purpose of this meta-analysis was to compare the assay sensitivity of 2 efficacy paradigms: pain intensity (calculated using summed pain intensity difference [SPID]) and pain relief (calculated using total pain relief [TOTPAR]).
Mean TOTPAR (total pain relief) or mean SPID (summed pain intensity difference) over 4 to 6 hours were either extracted, or calculated from pain data within each trial.
CPAT score changes were calculated after pain management.
We calculated averaged pain ratings subsequent to trigemino-nociceptive stimulation for every subject in every session.
Magnitude of effect was calculated for pain scores.
The sample size is calculated for pain intensity (numeric rating scale 0-10).
Percent improvement was calculated for pain (% change from baseline BPI score).
